BioLife Solutions (NASDAQ:BLFS) Major Shareholder Casdin Partners Master Fund, L Sells 300,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) major shareholder Casdin Partners Master Fund, L sold 300,000 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $22.65, for a total transaction of $6,795,000.00. Following the sale, the insider owned 5,657,165 shares of the company’s stock, valued at approximately $128,134,787.25. The trade was a 5.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Thursday, May 21st, Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00.
• On Wednesday, May 20th, Casdin Partners Master Fund, L sold 250,000 shares of BioLife Solutions stock. The shares were sold at an average price of $23.70, for a total transaction of $5,925,000.00.

BioLife Solutions Price Performance

Shares of BioLife Solutions stock opened at $24.74 on Friday. BioLife Solutions, Inc. has a 1 year low of $17.86 and a 1 year high of $29.62. The firm has a market cap of $1.21 billion, a PE ratio of -309.21 and a beta of 1.97. The company has a 50 day simple moving average of $20.58 and a two-hundred day simple moving average of $22.94.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The business had revenue of $27.50 million during the quarter, compared to analyst estimates of $25.66 million. As a group, research analysts anticipate that BioLife Solutions, Inc. will post 0.09 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Tudor Investment Corp ET AL increased its stake in shares of BioLife Solutions by 85.2% in the third quarter. Tudor Investment Corp ET AL now owns 111,356 shares of the medical equipment provider’s stock worth $2,841,000 after buying an additional 51,217 shares during the period. Capricorn Fund Managers Ltd purchased a new position in shares of BioLife Solutions in the fourth quarter worth $9,153,000. Vanguard Group Inc. increased its stake in shares of BioLife Solutions by 2.4% in the third quarter. Vanguard Group Inc. now owns 2,967,518 shares of the medical equipment provider’s stock worth $75,701,000 after buying an additional 70,248 shares during the period. Summit Creek Advisors LLC increased its stake in shares of BioLife Solutions by 24.2% in the fourth quarter. Summit Creek Advisors LLC now owns 238,802 shares of the medical equipment provider’s stock worth $5,774,000 after buying an additional 46,541 shares during the period. Finally, Public Sector Pension Investment Board increased its stake in shares of BioLife Solutions by 19.7% in the third quarter. Public Sector Pension Investment Board now owns 151,378 shares of the medical equipment provider’s stock worth $3,862,000 after buying an additional 24,913 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BLFS has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th. Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.